Perfluorobutane ultrasound contrast agent and methods for its manufacture and use

• US 5,701,899 A
• Filed: 05/31/1995
• Issued: 12/30/1997
• Est. Priority Date: 05/12/1993
• Status: Expired due to Term

• Current Assignee: Board of Regents of the University of Nebraska
• Original Assignee: Board of Regents of the University of Nebraska
• Inventors: Porter, Thomas R.
• Primary Examiner(s): JAWORSKI, FRANCIS J
• Application Number:
  US08/454,853
• Time in Patent Office: 944 Days
• Field of Search: 424/450, 424/9.52, 128/662.02
• US Class Current: 600/458
• CPC Class Codes: A61K 49/22 Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
• CPC Class Codes: A61K 49/223 Microbubbles, hollow microspheres, free gas bubbles, gas microspheres

Abstract

The invention relates to a new ultrasound contrast agent of the type which relies on microbubbles for echogenicity. The new contrast agent comprises microbubbles with an internal atmosphere enhanced with a perfluorobutane gas which is effective for visually detecting myocardial uptake upon echocardiogram following peripheral intravenous injection of said agent into a host. The contrast agent of this invention is unique in that it makes possible the non-invasive visual detection of myocardial uptake. In addition, the contrast agent of this invention makes feasible safe and consistent, non-invasive methods for visually assessing, qualitatively or quantitatively, not only myocardial perfusion, but renal and hepatic perfusion, and for detecting severity of coronary arterial stenosis.

Claims

1. A pharmaceutically acceptable ultrasound contrast agent which relies on microbubbles for echogenicity, said agent comprising:

microbubbles formed from a solution of a filmogenic protein and a saccharide wherein said saccharide comprises less than about 40% by weight of said solution wherein said microbubbles have an internal atmosphere enhanced with perfluorobutane gas.

2. The contrast agent of claim 1 wherein said filmogenic protein is human serum albumin.

3. The contrast agent of claim 2 wherein said human serum albumin is diluted 2 to 8 fold with dextrose.

4. The contrast agent of claim 3 wherein said human serum albumin is a 5% by weight solution.

5. The method of claim 4 wherein said dextrose is a 5% by weight solution.

6. The contrast agent of claim 1 wherein said saccharide is dextrose.

7. A sonicated aqueous albumin-dextrose ultrasound contrast agent solution comprising:

between about a two-fold and about an eight-fold dilution of aqueous albumin with between about 5% to about 50% by weight aqueous dextrose solution;

said albumin between about 2% to about 10% by weight solution; and

microbubbles the gaseous content of which contain an amount of perfluorocarbon gas which is effective for visually detecting myocardial perfusion upon echocardiogram following peripheral intravenous injection of said agent into a host.

8. The contrast agent of claim 7 wherein said dilution of albumin with dextrose is a 3-fold dilution.

9. The contrast agent of claim 8 wherein said human serum albumin is a 5% by weight solution.

10. The contrast agent of claim 8 wherein said dextrose is a 5% by weight solution.

11. A method for myocardial, renal or hepatic opacification comprising the steps of:

(a) obtaining an echo contrast agent solution which comprises;

(i) forming an aqueous albumin-dextrose solution containing between about a two-fold and about an eight-fold dilution of between about 5% to about 50 by weight dextrose and between about 2% to about 10% by weight human serum albumin, and

(ii) sonicating said mixture to form microbubbles the gaseous content of which contain an amount of perfluorocarbon gas which is effective for visually detecting myocardial perfusion by echocardiogram following peripheral intravenous injection of said agent into a host;

(b) introducing said echo contrast agent into a host by intravenous injection; and

(c) performing an echo contrast study on said host using a suitable Doppler or ultrasound echo apparatus.

12. A pharmaceutically acceptable contrast agent which relies on microbubbles for echogenicity, said agent comprising:

microbubbles with an interior atmosphere enhanced with perfluorobutane gas.

13. A pharmaceutically-acceptable ultrasound contrast agent which relies on microbubbles for echogenicity prepared by the method of:

combining a denaturable protein and a saccharide to form a solution wherein said saccharide comprises less than about 40% by weight of said solution;

perfusing said solution with fluorobutane gas;

sonicating said solution during said perfusion so that microbubbles are formed with an internal atmosphere comprising said perfluorobutane gas.

14. The method of claim 13 wherein said saccharide is dextrose.

15. The method of claim 13 wherein said protein is human serum albumin.